Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I, Roman M, Welch C, Entrialgo-Cadierno R, Salmon M, Santos A, Feliu I, Kovalski J, Lopez I, Rodriguez-Remirez M, Palomino-Echeverria S, Lonfgren SM, Ferrero M, Calabuig S, Ludwig IA, Lara-Astiaso D, Jantus-Lewintre E, Guruceaga E, Narayanan S, Ponz-Sarvise M, Pineda-Lucena A, Lecanda F, Ruggero D, Khatri P, Santamaria E, Fernandez-Irigoyen J, Ferrer I, Paz-Ares L, Drosten M, Barbacid M, Gil-Bazo I, Vicent S. Macaya I, et al. Among authors: ferrer i. Nat Commun. 2023 Oct 10;14(1):6332. doi: 10.1038/s41467-023-41828-z. Nat Commun. 2023. PMID: 37816716 Free PMC article.
Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.
Marrugal Á, Ojeda L, Paz-Ares L, Molina-Pinelo S, Ferrer I. Marrugal Á, et al. Among authors: ferrer i. Dis Markers. 2016;2016:2138627. doi: 10.1155/2016/2138627. Epub 2016 Jun 30. Dis Markers. 2016. PMID: 27445423 Free PMC article. Review.
A patent review of FGFR4 selective inhibition in cancer (2007-2018).
Quintanal-Villalonga A, Ferrer I, Molina-Pinelo S, Paz-Ares L. Quintanal-Villalonga A, et al. Among authors: ferrer i. Expert Opin Ther Pat. 2019 May 30;29(6):429-438. doi: 10.1080/13543776.2019.1624720. Print 2019 Jun. Expert Opin Ther Pat. 2019. PMID: 31146605 Review.
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J. Garmendia I, et al. Among authors: ferrer i. Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899. doi: 10.1164/rccm.201807-1292OC. Am J Respir Crit Care Med. 2019. PMID: 31166114 Free article.
KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. Ferrer I, et al. Lung Cancer. 2018 Oct;124:53-64. doi: 10.1016/j.lungcan.2018.07.013. Epub 2018 Jul 19. Lung Cancer. 2018. PMID: 30268480 Free article. Review.
Current Challenges in Cancer Treatment.
Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares L. Zugazagoitia J, et al. Among authors: ferrer i. Clin Ther. 2016 Jul;38(7):1551-66. doi: 10.1016/j.clinthera.2016.03.026. Epub 2016 May 2. Clin Ther. 2016. PMID: 27158009 Review.
1,334 results